Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 2154

Journal of Biotechnology & Biomaterials received 2154 citations as per Google Scholar report

Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Access to Global Online Research in Agriculture (AGORA)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • ICMJE
Recommended Journals
Share This Page

Veltis�?®: Innovative albumin based technology for half-life extension and optimization of biotherapeutics

Industrial Biotechnology Congress

Mikael Bjerg Caspersen

Novozymes Biopharma, UK

ScientificTracks Abstracts: J Biotechnol Biomater

DOI: 10.4172/2155-952X.S1.034

Abstract
Short circulatory half-life represents a major obstacle for many protein and peptide-based therapeutic agents, resulting in increased dosing with the consequent risk of side effects and reduced patient compliance. It has been demonstrated that the pharmacokinetics of small drugs, peptides and proteins can be significantly improved by conjugation, association or fusion to albumin. This extended circulatory half-life derives from both the size of albumin and recycling of the molecule via the neonatal Fc receptor, FcRn. Using advanced protein engineering expertise, human serum albumin has been modified to enhance its affinity for FcRn. This increase in affinity for the FcRn receptor translates into improved pharmacokinetic properties of the albumin molecule and ultimately the therapeutic candidate that is fused or conjugated to it. The application of these novel albumin variants to improve the pharmacokinetic properties of a number of therapeutic candidates, including proteins and small peptides will be exemplified and discussed.
Biography

Mikael Bjerg Caspersen has completed his PhD from The Technological University of Denmark and did Post-doctoral studies at The University of Copenhagen. He has a background working in the Analytical service industry from Ciphergen Biosystems and in the CMO industry from working at CMC Biologics. He is working at Novozymes Biopharma with the development and implementation of albumin based technologies for formulation and half-life extension.

Email: MBCP@novozymes.com

Top